Literature DB >> 29161630

Active epilepsy prevalence, the treatment gap, and treatment gap risk profile in eastern China: A population-based study.

Xiaoyan Ding1, Yang Zheng2, Yi Guo2, Chunhong Shen2, Shan Wang2, Feng Chen3, Shengqiang Yan2, Meiping Ding4.   

Abstract

We measured the prevalence of active epilepsy and investigated the treatment gap and treatment gap risk profile in eastern China. This was a cross-sectional population-based survey conducted in Zhejiang, China, from October 2013 to March 2014. A total 54,976 people were selected using multi-stage cluster sampling. A two-stage questionnaire-based process was used to identify patients with active epilepsy and to record their demographic, socioeconomic, and epilepsy-related features. Logistic regression analysis was used to analyze risk factors of the treatment gap in eastern China, as adjusted for age and sex. We interviewed 50,035 people; 118 had active epilepsy (2.4‰), among which the treatment gap was 58.5%. In multivariate analysis, failure to receive appropriate antiepileptic treatment was associated with higher seizure frequency of 12-23 times per year (adjusted odds ratio=6.874; 95% confidence interval [CI]=2.372-19.918), >24 times per year (adjusted odds ratio=19.623; 95% CI=4.999-77.024), and a lack of health insurance (adjusted odds ratio=7.284; 95% CI=1.321-40.154). Eastern China has relatively lower prevalence of active epilepsy and smaller treatment gap. Interventions aimed at reducing seizure frequency, improving the health insurance system should be investigated as potential targets to further bridge the treatment gap.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Active epilepsy; Eastern China; Prevalence rate; Risk factors; Treatment

Mesh:

Substances:

Year:  2017        PMID: 29161630     DOI: 10.1016/j.yebeh.2017.10.020

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  5 in total

1.  Overexpressed microRNA-494 represses RIPK1 to attenuate hippocampal neuron injury in epilepsy rats by inactivating the NF-κB signaling pathway.

Authors:  Yinbao Qi; Ruobing Qian; Li Jia; Xiaorui Fei; Dong Zhang; Yiming Zhang; Sen Jiang; Xianming Fu
Journal:  Cell Cycle       Date:  2020-04-19       Impact factor: 4.534

2.  Delay of Treatment, After Diagnosis, as a Contributor to the "Treatment Gap" in Epilepsy.

Authors:  R Edward Hogan
Journal:  Epilepsy Curr       Date:  2019-09-17       Impact factor: 7.500

3.  Sociodemographic factors associated with the first administration of anti-seizure medication in patients with focal epilepsy in Western China.

Authors:  Qiong Zhu; Yi Guo; Shuai Ma; Lili Yang; Zhonghua Lin; Hongbin Sun; Guangzong Li; Liang Yu
Journal:  BMC Neurol       Date:  2021-06-29       Impact factor: 2.474

Review 4.  The impact of social, national and community-based health insurance on health care utilization for mental, neurological and substance-use disorders in low- and middle-income countries: a systematic review.

Authors:  Sumaiyah Docrat; Donela Besada; Susan Cleary; Crick Lund
Journal:  Health Econ Rev       Date:  2020-04-24

5.  Value of Perampanel as Adjunctive Treatment for Partial-Onset Seizures in Epilepsy: Cost-Effectiveness and Budget Impact Analysis.

Authors:  Donger Zhang; Xia Li; Jing Ding; Xiatong Ke; Wenpei Ding; Yinan Ren; He Xu; Hongchao Li; Aixia Ma; Wenxi Tang
Journal:  Front Public Health       Date:  2021-07-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.